05th March 2021
Professor Leonard Calabrese offers the latest advice on managing rheumatic patients during the pandemic and Professor Kimme Hyrich discusses the learnings from the COVID-19 Global Rheumatology Alliance registries, a year on from their inception.
03rd March 2021
Dr Lee Simon, Principal Scientist in SDG LLG, Cambridge, US. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Lee Simon discusses pain in RA
03rd March 2021
Professor Tsutomu Takeuchi, Vice-President at Keio University and Professor of Medicine in the Division of Rheumatology and Clinical Immunology at Keio University School of Medicine. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Tsutomu Takeuchi discusses how upadacitinib monotherapy vs methotrexate monotherapy in methotrexate-naïve Japanese patients with RA
19th February 2021
Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor René Westhovens discusses his latest paper on use of filgotinib in combination with methotrexate or as filgotinib monotherapy versus methotrexate monotherapy in patients with active RA.
19th February 2021
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
29th January 2021
Founder and President of the Association of Women in Rheumatology. In this podcast Dr Grace Wright discusses her career and the future of AWIR.
27th January 2021
Professor György Nagy from the Semmelweis University, Hungry. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor György Nagy discusses his latest paper on EULAR definition of difficult-to-treat RA
18th January 2021
Professor Philip Mease from the University of Washington School of Medicine. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Professor Philip Mease discusses his latest paper on Upadacitinib for Psoriatic Arthritis refractory to biologics.
18th January 2021
Prof Iain McInnes discusses JAK inhibitors and TNFi in RA treatment. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
11th January 2021
In this podcast the Past President of ACR, Professor Michael Weinblatt discusses his involvement in the development of methotrexate and the expansion of his unit at the Brigham, alongside Professor Paul Emery.
06th January 2021
Prof Josef Smolen from Medical University of Vienna. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Josef Smolen discusses efficacy of baricitinib in patients with RA
30th December 2020
Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas, discusses data from the SELECT-COMPARE trial, where patients with RA were switched between upadacitinib and adalimumab in cases of insufficient response.
29th December 2020
Dr Andreas Kerschbaumer from Vienna University. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Andreas Kerschbaumer discusses his systematic review paper on “Points to Consider for the Treatment of Immune Mediated Inflammatory Diseases with Janus Kinase Inhibitors.
22nd December 2020
Prof Iain McInnes discusses JAK inhibitors. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
22nd December 2020
Prof Kevin Winthrop from OHSU. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Kevin Winthrop discusses aged based incidence of infections with tofacitinib
09th December 2020
Past President of EULAR and Carol Nachman Prize winner. In this podcast, Professor Paul Emery discusses his work in managing early RA and the growth of his unit at Leeds into a world leading centre for rheumatology research alongside Professor Michael Weinblatt.
25th November 2020
Prof Iain McInnes discusses upadacitinib safety. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
24th November 2020
Prof Stanley Cohen - University of Texas. Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Stanley Cohen discusses safety profile of upadacitinib
17th November 2020
Dr Gustavo Citera, Head of Rheumatology at the Institute of Psychophysical Rehabilitation, Buenos Aires, Argentina. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Gustavo Citera discusses how JAK inhibition could be associated with interstitial lung disease events.
04th November 2020
Prof Iain McInnes discusses the use of baricitinib to treat COVID-19 and a JAK inhibitor, itacitinib. Keep up-to-date with the latest information in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
15th October 2020
Professor of Rheumatology at University Medical Centre, Utrecht. In this podcast, Professor Bijlsma discusses what attracted him to the field of rheumatology, the major advances in immunological knowledge leading to tsDMARDs and the importance of Treat-to-Target. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research, and views on developments in inflammation.
06th October 2020
Professor of Rheumatology in the Department of Internal Medicine - Hospital de Clínicas at the Federal University of Paraná, Brazil. In this podcast, Professor Azevedo discusses what attracted him to rheumatology and how biosimilars have evolved in Latin America.
02nd October 2020
Dr Pedro López-Romero, a senior research scientist from Lilly, and Dr Eugen Feist from the Charité. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, they discuss anti-CarbV and anti-MCV titres as predictors for improvements in SDAI score and radiographic progression in patients with RA.
02nd October 2020
Kevin Winthrop, Professor of Infectious Diseases and Public Health at the Oregon Health & Science University in Portland, Oregon. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Winthrop discusses infections in baricitinib clinical trials for patients with active RA.
29th September 2020
Prof Iain McInnes discusses the risk of infection and cardiovascular events associated with JAK inhibitors. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
18th September 2020
Pharmacoepidemiology research group leader at the German Rheumatism Research Centre, Berlin, Germany, and Scientific Director of the Institute of Musculoskeletal Health, Madrid, Spain. In this podcast, Professor Strangfeld and Professor Carmona discuss the use of registries in the field of rheumatology, giving insight into their experiences with developing data collection strategies over the years and translating it to clinical research.
11th September 2020
Vice Chair of the Cleveland Clinic's Department of Rheumatic and Immunologic Diseases in Cleveland, Ohio. In this podcast, Prof Leonard Calabrese discusses his interest in rheumatology, his work considering the interface between rheumatic diseases and infection, and the significance of herpes zoster in inflammatory disease. Perspectives in Inflammation is a series of in-depth interviews revealing what attracted world leading experts to the field of inflammation, their current research interests, and views on the latest developments in inflammation.
27th August 2020
Vibeke Strand, Adjunct Clinical Professor in the Division of Immunology and Rheumatology in the Stanford University School of Medicine. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Vibeke Strand discusses the safety and efficacy of upadacitinib monotherapy in RA.
26th August 2020
Chair of Department of Rheumatology in the Hospital Italiano, Buenos Aires, Argentina. In this podcast, Dr Soriano discusses his interest in Rheumatology, and his current research collaboration across Argentina.
21st August 2020
Professor Roy Fleischmann from the University of Texas Southwestern Medical Center, Dallas. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the safety and efficacy of long-term baricitinib monotherapy in RA.
21st August 2020
Prof Iain McInnes discusses the safety and efficacy of baricitinib and upadacitinib monotherapy in RA management. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
06th August 2020
Chief of the Allergy Immunology and Rheumatology Division and Executive Committee Member of the Center for Musculoskeletal Research. In this podcast, Prof Chris Ritchlin discusses how he became involved in rheumatology.
06th August 2020
Prof Kosuke Ebina from the University of Osaka, Japan. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kosuke Ebina discusses drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with RA using real-world data from the ANSWER registry.
31st July 2020
Professor Georg Schett from the University of Erlangen-Nuremberg. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Georg Schett discusses SARS-CoV-2 seroconversion in patients with immune-mediated inflammatory diseases receiving cytokine inhibitors.
22nd July 2020
Prof Iain McInnes discusses the long term safety of tofacitinib in PsA and drug retention.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
07th July 2020
Past president of EULAR, incoming president of ILAR and the Associate Editor of the Journal of Clinical and Experimental Rheumatology. In this podcast, Prof Maurizio Cutolo discusses circadian rhythms in inflammation alongside Prof Kevin Winthrop from Oregon Health and Science University.
03rd July 2020
Kennedy Professor of Translational Rheumatology at the Universities of Birmingham and Oxford.
In this podcast, Prof Chris Buckley discusses his contribution to A-TAP for which he received the prestigious Carol Nachman prize in 2020.
26th June 2020
Professor Axel Finckh from the Universirty of Geneva.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Axel Finckh discusses drug maintenacne in a Swiss RA population.
23rd June 2020
Dr Stanley Cohen from Southwestern Medical School. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Dr Stanley Cohen discusses a phase 2 trial of BTK inhibitor, fenebrutinib.
23rd June 2020
Professor Gerd Burmester from the Charité. Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Gerd Burmester discusses the safety of tofacitinib in PsA and evaluates Hep B in baricitinib trials.
22nd June 2020
Prof Iain McInnes discusses the safety profile and temporary interruption of baricitinib.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section.
17th June 2020
Gain insight into the latest research presented at EULAR 2020.
Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition includes some great basic science abstracts from Professor Iain McInnes and Professor Thomas Dörner.
17th June 2020
Gain insight into the latest research presented at EULAR 2020.
Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on the safety of JAK inhibitors and features presentations from; Professor Leonard Calabrese, Professor Kevin Winthrop, Professor Iain McInnes and Professor Anja Strangfeld.
16th June 2020
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on JAK inhibitors featuring presentations from; Professor Maya Buch, Professor Paul Emery, Professor Roy Fleischmann, Professor Peter Nash and Dr Kim Lauper
12th June 2020
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on patient reported outcomes and real-world data featuring presentations from; Professor Rieke Alten, Professor Vibeke Strand, Professor Axel Finckh, and Dr Kelly Gavigan.
11th June 2020
Gain insight into the latest research presented at EULAR 2020. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors. This edition focuses on JAK inhibitors and emerging treatments in therapy areas beyond RA, featuring presentations from; Professor Peter Nash, Professor Xenofon Baraliakos, Professor Atul Deodhar, Professor David Isenberg.
06th June 2020
Prof Edwards presents the Day 4 highlights of the key abstracts and posters presented at EULAR 2020.
05th June 2020
Prof Edwards presents the Day 3 highlights of the key abstracts and posters presented at EULAR 2020.
04th June 2020
Prof Bijlsma presents the Day 2 highlights of the key abstracts and posters presented at EULAR 2020.
03rd June 2020
Prof Bijlsma presents the Day 1 highlights of the key abstracts and posters presented at EULAR 2020.
02nd June 2020
A preview of the latest research at EULAR 2020.
Prof Bijlsma presents a preview of the upcoming EULAR 2020 congress, highlighting important abstracts in cytokine signalling.
27th May 2020
Prof Iain McInnes discusses PsA & Hep B.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section.
11th May 2020
The global effort improving patient outcomes amid COVID-19.
Prof Peter Nash discusses the global rheumatology register for COVID-19 with Prof Philip Robinson.
04th May 2020
Prof Kevin Winthrop from Oregon Health & Science University.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition Prof Kevin Winthrop discusses the long-term effectiveness of the live zoster vaccine
04th May 2020
Prof Iain McInnes discusses vasculitis and zoster.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section.
24th April 2020
The global effort improving patient outcomes amid COVID-19.
Past President of EULAR Prof Johannes Bijlsma discusses global rheumatology registries for COVID-19 with EULAR registry group member Prof Kimme Hyrich.
22nd April 2020
COVID-19 guidance for rheumatologists.
Prof Peter Nash discusses the challenges COVID-19 poses with infections specialist Prof Kevin Winthrop.
09th April 2020
First to identify destructive properties of IL-17 and received the prestigious Carol Nachman prize in 2010 for his contribution. In this podcast, Prof Pierre Miossec discusses the pathophysiology of RA alongside Prof Tsutomu Takeuchi from Keio University.
03rd April 2020
Timo Gaber and Paula Hoff from Charité Berlin.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, the impact of tofacitinib on the bone healing process is discussed.
27th March 2020
Prof Schett from University of Erlangen-Nuremberg.
Join Prof Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Prof Schett discusses how JAK inhibitors can increase bone formation by stimulating osteoblasts.
23rd March 2020
Prof Iain McInnes discusses bone homeostasis.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed in this podcast is available in a more detailed slide format in the publications section at cytokinesignalling.com.
11th March 2020
Muirhead Professor of Medicine, President of EULAR, and Sir James Black Prize Medal winner. In this podcast, Prof Iain McInnes discusses the inception of JAK inhibitors during his time at the National Institutes of Health with Prof Peter Nash from the University of Queensland.
27th February 2020
Dr Giovanni Orsolini from the University of Verona.
Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Dr Giovanni Orsolini discusses the potential of JAK inhibitors to halt bone erosion, independent of their effects on inflammation.
21st February 2020
Prof Iain McInnes discusses JAK selectivity.
Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
07th February 2020
Head of the Division of Rheumatology at Karolinska Institute and a co-author of more than 100 articles in peer review journals. In this podcast, Prof Anca Catrina discusses the role of antibodies in the pathogenesis of RA with Prof Johannes Bijlsma from University Medical Centre, Utrecht.
29th January 2020
Prof Vibeke Strand from Stanford University.
Join Prof Peter Nash as he interviews notable figures in rheumatology. In this edition Prof Vibeke Strand discusses improvements in patient-reported outcomes with upadacitinib.
Effects of Upadacitinib on Patient-Reported Outcomes: Results from SELECT-BEYOND and SELECT-NEXT.
22nd January 2020
Iain McInnes discusses patient-reported outcomes. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
10th January 2020
Member of the US Centers for Disease Control and a co-author of more than 100 publications. In this podcast, Prof Kevin Winthrop discusses the impact concomitant treatments have on HZ risk with Professor Maurizio Cutolo from the University of Genova.
23rd December 2019
Safety of Baricitinib in East Asian Patients With Moderate to Severe Active Rheumatoid Arthritis
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis
23rd December 2019
Professor McInnes presents the Highlights of 2019.
We can be optimistic that clinical practice for inflammatory arthritis will continue to improve, with promising long-term safety data supporting the use of established JAK inhibitors; tofacitinib and baricitinib, in addition to exciting phase III clinical data for filgotinib and newly approved upadacitinib.
28th November 2019
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis...
Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta?Analysis of Randomized Controlled Trials...
24th November 2019
In this edition of Congress Author Podcasts, recorded at ACR 2019, the latest data from the FINCH studies are presented by Professors Taylor, Westhovens and Winthrop, in addition to filgotinib safety data from a phase 2 Psoriatic Arthritis trial, presented by Professor Coates.
Download the Posters Here
23rd November 2019
In this edition of Congress Author Podcasts, recorded at ACR 2019,
real-world tofacitinib safety data is presented by Professor Joel Kremer and the impact of baricitinib and tofacitinib on pain is analysed by Professors Peter Taylor and Maxime Dougados.
Download the Posters Here
22nd November 2019
Introducing Congress Author Podcasts, a new podcast series where authors review their congress posters and presentations on cytokine signalling and JAK inhibitors. The first edition, recorded at ACR 2019 in Atlanta, focuses on upadacitinib.
Download the Posters Here
19th November 2019
Professor Kevin Winthrop and Professor Leonard Calabrese present the key abstracts presented at this year's ACR conference in Atlanta.
31st October 2019
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib
26th September 2019
Professor Iain McInnes joined by Professor Johannes Bijlsma, discusses the changes required to educate the next generation of rheumatologists, highlighting the benefits of online educational courses and the importance of quality amid a plethora of information.
26th September 2019
Comparison of Baricitinib, Upadacitinib, and Tofacitinib Mediated Regulation of Cytokine Signalling in Human Leukocyte Subpopulations...
Outcomes of Dose Reduction, Withdrawal, and Restart of Tofacitinib in Patients with Rheumatoid Arthritis: A Prospective Observational Study...
19th September 2019
Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients with Rheumatoid Arthritis Over 48 Weeks with Switch to Alternate Therapy in Patients with Insufficient Response....
Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double-Blind, Randomized Controlled Trial....
09th September 2019
27th August 2019
Safety and Effectiveness of Upadacitinib or Adalimumab Plus Methotrexate in Patients with Rheumatoid Arthritis Over 48 Weeks...
Efficacy and Safety of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate...
14th August 2019
29th July 2019
Clinical Outcomes in Patients Switched from ADA to BARI due to Non-response and/or Study Design: Phase III in Patients with Rheumatoid Arthritis...
Live Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, or Adalimumab with Methotrexate...
27th June 2019
Upadacitinib as Monotherapy in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate (SELECT-MONOTHERAPY)...
Impact of Janus Kinase Inhibitors on Risk of Cardiovascular Events in Patients with Rheumatoid Arthritis...
30th May 2019
23rd May 2019
Evaluation of Pneumococcal and Tetanus Vaccine Responses in Patients with Rheumatoid Arthritis Receiving Baricitinib: Results from a Long-Term Extension Trial Substudy...
Safety and Efficacy of Tofacitinib For Up to 9.5-Years in The Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study...
10th May 2019
25th April 2019
Efficacy and Safety Data Based on Historical or Pre-Existing Conditions at Baseline for Patients with Active Rheumatoid Arthritis Who Were Treated with Baricitinib...
Tuberculosis, Hepatitis B and Herpes Zoster in Tofacitinib-Treated Patients with Rheumatoid Arthritis...
23rd April 2019
10th April 2019
22nd March 2019
Baricitinib Induces LDL-C and HDL-C Increases in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials...
Network Meta-Analysis of Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients...
13th March 2019
04th March 2019
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis...
Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study...
28th January 2019
Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis...
A Pooled analysis of the Safety of Tofacitinib as Monotherapy or in Combination with Background Conventional Synthetic Disease-Modifying Antirheumatic Drugs in a Phase 3 Rheumatoid Arthritis Population...
11th January 2019
Influence of Age and Renal Impairment on the Steady State Pharmacokinetics of Filgotinib, a Selective JAK1 Inhibitor...
Evaluation of the Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in Patients with Rheumatoid Arthritis...
07th January 2019
04th December 2018
Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...
30th November 2018
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids...
Herpes zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate...
16th November 2018
- Dr Alan Kivitz discussing his SYK inhibitor data: 00:00-2:09
- Dr Rebecca Kunder talks about the FIL safety study: 2:10-8:12
- Dr Heather Litman describes real-world immunomodulator data: 8:13-10:55
- Professor Roy Fleischmann analyses BARI rescue data: 10.56-15.02
- Dr Lucia Domínguez-Casas reviewes respiratory infection factors: 15.03-17:00
- Professor Peter Taylor with Dr Amer Mirza discuss JAK inhibitor biomarkers: 17:01-18:57
29th October 2018
Dose Reduction of Baricitinib in Patients with Rheumatoid Arthritis Achieving Sustained Disease Control: Results of a Prospective Study...
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment...
09th October 2018
Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab...
Lipid Profile and Effect of Statin Treatment in Pooled Phase II and Phase III Baricitinib Studies...
03rd October 2018
28th August 2018
Tocilizumab Discontinuation After Attaining Remission in Patients with Rheumatoid Arthritis who were Treated with Tocilizumab Alone or in Combination with Methotrexate...
Two Years of Sarilumab in Patients with Rheumatoid Arthritis and an Inadequate Response to MTX...
24th August 2018
25th July 2018
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (SELECT-NEXT)...
Safety and Efficacy of Upadacitinib in Patients with Active Rheumatoid Arthritis Refractory To Biologic Disease-Modifying Anti-Rheumatic Drugs (SELECT-BEYOND)...
30th June 2018
Long-term Radiographic and Patient-reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib...
Effects of Baricitinib on Radiographic Progression of Structural Joint Damage at 1 year...
30th May 2018
23rd May 2018
Tofacitinib in Rhuematoid Arthritis: Lack of Early Change in Disease Activity Predicts...
Evaluation of Disease Activity in Patients with Rheumatoid Arthritis Treated with Tofacitinib by RAPID3..
27th April 2018
Effectiveness and Safety of Tofacitinib in Rheumatoid Arthritis: a Cohort Study...
Effect of Filgotinib, a Selective JAK1 Inhibitor, with or without Methotrexate in Patients with Rheumatoid Arthritis: Patient-Reported Outcomes..
29th March 2018
Response to Baricitinib based on Prior Biologic Use in Patients with Refractory Arthritis...
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis...
Worldwide, 3-year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis...
29th March 2018
28th February 2018
Tofacitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Chinese Patients with Rheumatoid Arthritis: Patient-reported Outcomes...
Radiographic Joint Damage in Early Rheumatoid Arthritis Patients: Comparing Tocilizumab- and Methotrexate-based...
28th February 2018
02nd February 2018
29th January 2018
Patient-Reported Outcomes in Newly Diagnosed Early Rheumatoid Arthritis Patients Treated to Target with a Tocilizumab- or Methotrexate-based Strategy...
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including...
21st December 2017
Long-term Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis, Stratified by Number of Previous Treatment Failures with Biologic Agents: Results from the German RABBIT Cohort...
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naive and Experienced Patients...
30th November 2017
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA...
Safety and Efficacy of Baricitinib in Elderly Patients with Rheumatoid Arthritis...
30th October 2017
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program...
Patient-reported Outcomes of Baricitinib in Patients with Rheumatoid Arthritis and...
21st September 2017
Patient-reported Outcomes from a Phase 3 Study of Baricitinib versus...
Herpes Zoster and Tofacitinib Therapy in Patients with Rheumatoid Arthritis...
21st August 2017
Treatment Persistence and Clinical Outcomes of Tumor Necrosis Factor...
Analysis of Non-melanoma Skin Cancer across the Tofacitinib ...
25th July 2017
Efficacy and Safety of Tofacitinib Monotherapy...
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib...
26th June 2017
Outcomes of Tumor Necrosis Factor Inhibitor Cycling versus...
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor...
Biologics or Tofacitinib for People with Rheumatoid Arthritis Naïve to Methotrexate...
30th April 2017
EULAR RA Management Task Force, Ann Rheum Dis Published Online First: 06March2017. doi:10.1136/annrheumdis-2016-210715
Winthrop, Nature Reviews Rheumatology 2017;13:234–43
31st March 2017
20th October 2016
Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum
15th September 2016
Prof. McInnes reviews the latest papers uploaded to the Cytokine Signalling Forum
26th July 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Genovese and Prof. Takeuchi
View our CME Courses
25th February 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. J Zhang and Prof. Y Kaneko
20th January 2016
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. Laure Gossec
22nd December 2015
Prof. McInnes presents the CSF monthly podcast reviewing papers from Prof. V Strand and Prof. C Gabay.
21st October 2015
Steering Committee chair Prof. Iain McInnes introduces his picks of the most important abstracts presented at ACR 2015.
21st October 2015
Prof. Iain McInnes presents the inaugural monthly podcast reviewing papers by Prof. Wei Gao and Prof. Cem Gabay focusing on tofacitinib and tocilizumab respectively.